TMS therapy for Highland Beach — FDA-cleared TRD care, 12 minutes from home.

For Highland Beach residents from Bel Lido Isle to Toscana, RECO Health is the closest program running TMS on both standard and deep coil platforms with an in-house psychiatrist directing the case — not a technician working from an outside prescriber's referral. The seven-mile drive up A1A puts patients in the treatment chair in twelve minutes, and the same team that runs TMS also manages medications, ketamine, and structured outpatient care when the case needs more than one modality. Prior authorization is handled by the psychiatrist directly, which shortens the timeline from consult to first mapping session.

Highland Beach occupies the narrow oceanfront corridor between Delray and Boca Raton, and the drive up A1A to RECO Health’s Delray Beach campus runs about twelve minutes in typical morning traffic. For residents of Bel Lido Isle, Toscana, Ocean Cove, and the Boca Cove pocket whose depression has failed to respond to sertraline, escitalopram, or bupropion trials, that seven-mile drive opens direct access to a full FDA-cleared repetitive Transcranial Magnetic Stimulation program rather than a general-psychiatry referral loop. RECO’s in-house psychiatry team runs TMS therapy on both standard and deep coil platforms, integrated with the same team that manages ketamine, medication management, and structured outpatient care when a case needs more than one modality.

Who is a candidate for rTMS

The insurance-covered indication for rTMS is major depressive disorder with documented failure of at least two adequate antidepressant trials. “Adequate” is a specific claim: therapeutic dose, minimum four to six weeks at that dose, and confirmed adherence. A patient who tried sertraline 50 mg for three weeks and stopped due to side effects does not qualify; a patient who reached 150 mg for eight weeks with a PHQ-9 that never dropped below 15 does. RECO’s psychiatry team pulls pharmacy fill records, prescriber notes, and dose-response history to build the prior authorization packet — insurers deny on incomplete documentation more often than on genuine ineligibility.

Clinical candidacy extends beyond the insurance definition. Screening rules out ferromagnetic implants within 30 cm of the coil (cochlear implants, deep-brain stimulators, aneurysm clips), any personal or first-degree family seizure history, and active substance use that would confound both the safety profile and the response signal. Bipolar depression is not an absolute contraindication but requires an active mood stabilizer — lithium or lamotrigine — before enrollment to protect against manic switch. Patients with obsessive-compulsive disorder are evaluated separately for the deep TMS OCD protocol, which uses a different coil geometry and stimulation target, with YBOCS as the primary outcome measure.

The 36-session protocol and what treatment actually looks like

Session one is motor threshold mapping. The technician positions the figure-eight coil over the motor cortex and delivers single pulses at ascending intensity until a reliable thumb twitch — the abductor pollicis brevis contraction — appears at fifty percent of trials. That intensity is the resting motor threshold, and treatment intensity is set at 120% of that value. The coil then shifts anteriorly to the left dorsolateral prefrontal cortex, either by the 5.5 cm rule or by neuronavigation, depending on the platform.

Standard high-frequency treatment delivers approximately 3,000 pulses per session at 10 Hz — four seconds on, twenty-six seconds off, for roughly 37 minutes in the chair. Sessions two through thirty run Monday through Friday for six consecutive weeks. The final six sessions are a structured taper: three per week for two weeks, then two, then one. Patients drive themselves in, sit upright in a treatment chair, and typically read or listen to podcasts through the session. The only common acute side effect is mild scalp discomfort or a tension-type headache in the first week, which resolves as the tissue accommodates. Same-day return to work is standard.

Response, remission, and the second-course question

Published response rates for rTMS in treatment-resistant depression run 40-60% depending on the response definition — typically a fifty-percent reduction in PHQ-9 or Hamilton-D score — and remission rates, defined as PHQ-9 below 5 or HAM-D below 7, run 25-40%. Response usually emerges between sessions 15 and 25, with continued gains through the taper. RECO tracks PHQ-9 and GAD-7 weekly through treatment and adjusts based on trajectory rather than on any single week’s score.

Non-responders at session 20-25 trigger a case review. Sometimes the coil position warrants adjustment — a subset of patients have DLPFC anatomy that the 5.5 cm rule misses. Sometimes the case warrants a switch to intermittent theta burst, or a pivot to the ketamine or esketamine (Spravato) pathway that RECO also operates in-house. Responders who later relapse — typically at eight to eighteen months post-treatment — are candidates for a second full course, and insurers routinely approve second courses when the first produced documented remission.

iTBS and the shorter-session option

Intermittent Theta Burst Stimulation is an FDA-cleared alternative rTMS protocol first validated in the THREE-D trial, which demonstrated non-inferiority to standard 10 Hz treatment. iTBS compresses the 3,000-pulse dose into a three-minute session using short bursts at 50 Hz. For clients whose work schedule cannot absorb a 37-minute daily treatment window, iTBS makes daily attendance realistic without compromising the evidence base.

Not every commercial insurance plan reimburses iTBS at parity with standard high-frequency rTMS, and prior authorization language sometimes specifies the older protocol. RECO’s admissions team confirms plan-specific coverage before enrolling. Accelerated iTBS schedules — the Stanford SAINT protocol delivers ten sessions per day over five days — are available on a self-pay basis but are not yet reliably covered by commercial insurance.

What to expect on your first visit

Initial evaluation is a full psychiatric consult with RECO’s TMS psychiatrist rather than a technician intake. The clinician confirms the MDD diagnosis, administers PHQ-9, GAD-7, and the Columbia Suicide Severity Rating Scale, and reviews the treatment history in detail — every prior antidepressant, dose, duration, response, and reason for discontinuation. If pharmacy records aren’t already on file, the team pulls them.

The safety screen covers seizure history, traumatic brain injury, syncope, and any metallic implants near the head. Current medications are reviewed for seizure-threshold effects — bupropion above 300 mg, tramadol, clozapine — which don’t automatically disqualify but shift the risk-benefit calculation. Once candidacy is confirmed, the prior authorization goes out the same week. Peer-to-peer reviews are handled by the RECO psychiatrist directly, which shortens the approval timeline compared with practices that route authorizations through billing staff.

Insurance and admissions from Highland Beach

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS across most product lines. Prior authorization for rTMS typically clears in 7-21 days once documentation is complete; the mapping session is scheduled the following week. Out-of-pocket cost after coverage is usually the plan’s specialty-visit copay per session — patients should verify their specific benefit before enrolling.

From most Highland Beach addresses, the drive is A1A north to Linton Boulevard — roughly seven miles and twelve minutes outside of season, closer to eighteen minutes in February. Morning treatment slots between 7:00 and 9:00 AM are the most requested by working professionals in Bel Lido and Toscana; midday slots typically have more availability. Admissions can be reached directly to verify coverage and begin the intake process.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.